These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9056749)

  • 1. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
    Westerhuis LW; Delaere KP
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M; Jensen LT; Iversen P
    Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T; Sakai H; Kanetake H; Saito Y
    Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
    Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
    Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
    Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
    Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
    Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
    Akimoto S; Furuya Y; Akakura K; Ito H
    Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
    Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours. Comparison with the results of 99mTc-methylene bisphosphonate bone scintigraphy.
    Withold W; Georgescu G; Khakzad H; Vosberg H; Mueller-Gaertner HW; Reinauer H
    Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):479-85. PubMed ID: 8547430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
    Noguchi M; Yahara J; Noda S
    Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma.
    Yoshida K; Hosoya Y; Arai K; Sumi S; Honda M
    Clin Chim Acta; 1996 Oct; 254(1):93-5. PubMed ID: 8894314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.